You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: April 8, 2025

Litigation Details for Degui Chen v. Michael E. Jung (C.D. Cal. 2018)


✉ Email this page to a colleague

« Back to Dashboard


Small Molecule Drugs cited in Degui Chen v. Michael E. Jung
The small molecule drug covered by the patents cited in this case is ⤷  Try for Free .

Details for Degui Chen v. Michael E. Jung (C.D. Cal. 2018)

Date FiledDocument No.DescriptionSnippetLink To Document
2018-03-12 254 Judgment Degui Chens claim for inventorship of U.S. Patent No. 8,445,507 is dismissed with prejudice. (2) Plaintiff…Chen’s claim for inventorship of U.S. Patent No. 5 8,445,507 is dismissed with prejudice. 6 …Plaintiff Degui Chens claim for inventorship of U.S. Patent No. 8,802,689 is dismissed with prejudice. (3) …Plaintiff Degui Chens claim for inventorship of U.S. Patent No. 9,388,159 is dismissed with prejudice. (jp…Plaintiff Degui Chen’s claim for inventorship of U.S. Patent No. 7 8,802,689 is dismissed with prejudice. External link to document
>Date Filed>Document No.>Description>Snippet>Link To Document
Showing 1 to 1 of 1 entries

Degui Chen v. Michael E. Jung: A Litigation Summary and Analysis

Case Overview

Degui Chen v. Michael E. Jung is a legal case that was heard in the U.S. District Court for the Central District of California, case number 2:18-cv-02015-RGK-KS. Here is a detailed summary and analysis of the key points of this litigation.

Background

The case involves a dispute between Degui Chen and Michael E. Jung, with the specifics of the dispute not explicitly outlined in the available sources. However, the case is significant due to the legal issues it raises and the rulings that were made.

Procedural History

  • The case was filed in 2018 and proceeded through various stages, including motions and hearings.
  • A notable event in the case was the denial of a motion for summary judgment filed by the defendants. This decision was made by the U.S. District Court for the Central District of California in 2019[5].

Key Rulings and Decisions

Denial of Summary Judgment

  • The court denied the defendants' motion for summary judgment, which means that the court found there were genuine issues of material fact that needed to be resolved through a trial. This decision indicates that the court believed there was sufficient evidence to warrant further litigation rather than dismissing the case outright[5].

Legal Implications

Burden of Proof

  • The denial of the summary judgment motion highlights the importance of the burden of proof in civil cases. The defendants failed to demonstrate that there were no genuine issues of material fact, which is a requirement for granting a summary judgment.

Trial Proceedings

  • Following the denial of the summary judgment, the case would have proceeded to trial unless a settlement was reached. The trial would have involved the presentation of evidence and testimony to resolve the disputed facts.

Analysis

Significance of the Ruling

  • The ruling in Chen v. Jung underscores the stringent standards for granting summary judgments. It emphasizes that courts will not dismiss cases without ensuring that all relevant facts have been considered and that the moving party has met the high burden of proof required for summary judgment.

Impact on Future Cases

  • This case serves as a precedent for future litigants, particularly in the Central District of California. It reinforces the importance of thorough evidence presentation and the need for defendants to demonstrate conclusively that there are no genuine issues of material fact.

Conclusion

Degui Chen v. Michael E. Jung is a significant case that highlights the procedural and substantive legal issues involved in civil litigation. The denial of the summary judgment motion by the court underscores the importance of careful consideration of evidence and the high standards required for summary judgments.

Key Takeaways

  • Summary Judgment Standards: The case emphasizes the strict standards for granting summary judgments, requiring that there be no genuine issues of material fact.
  • Burden of Proof: The defendants must demonstrate conclusively that there are no disputed facts, a high burden to meet.
  • Procedural Implications: The denial of summary judgment means the case proceeds to trial, ensuring that all facts are fully considered.
  • Precedent: The ruling sets a precedent for future cases in the Central District of California, reinforcing the importance of thorough evidence presentation.

FAQs

  1. What was the main issue in Degui Chen v. Michael E. Jung?

    • The main issue was the defendants' motion for summary judgment, which the court denied due to the presence of genuine issues of material fact.
  2. What is the significance of the denial of summary judgment?

    • The denial indicates that the court found sufficient evidence to warrant a trial, emphasizing the high burden of proof required for summary judgments.
  3. What are the implications for future cases?

    • The case sets a precedent for the strict standards required for summary judgments and the importance of thorough evidence presentation.
  4. What happens next after a summary judgment is denied?

    • The case proceeds to trial, where all disputed facts are resolved through the presentation of evidence and testimony.
  5. Why is the burden of proof important in this case?

    • The burden of proof is crucial because the defendants must demonstrate conclusively that there are no genuine issues of material fact to succeed in their motion for summary judgment.

Sources

  1. Chen v. Jung (C.D. Cal. 2019) - JD Supra
  2. Degui Chen v. Jung, 2020-1257 - Casetext
  3. U.S. District Court for the Central District of California - Court Records

More… ↓

⤷  Try for Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.